Attached files
| file | filename |
|---|---|
| EX-3.1 - ARTICLES OF AMENDMENT - Panbela Therapeutics, Inc. | cimmaron_ex31.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2015
|
Cimarron Medical, Inc. |
|
(Exact name of registrant as specified in its charter) |
|
Utah |
000-55242 |
87-0543922 |
||
|
(State or other jurisdiction of |
(Commission File Number) |
(IRS Employer Identification No.) |
|
10 W. Broadway, Ste. 700 Salt Lake City, UT |
84101 |
|
|
(Address of Principal Executive Offices) |
(Zip Code) |
|
(801) 532-3080 |
|
(Registrant’s telephone number, including area code) |
|
Cimarron Software, Inc. |
|
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On May 29, 2015, the registrant filed Articles of Amendment with the State of Utah to change its name from “Cimarron Software, Inc.” to “Cimarron Medical, Inc.”
Item 9.01. Exhibits.
The following exhibits are filed with this report:
|
Exhibit Number |
Description of Exhibit |
|
|
3.1 |
Articles of Amendment filed May 29, 2015. |
|
2
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CIMARRON MEDICAL, INC. |
||
| Date: June 1, 2015 |
By: |
/s/ David Fuhrman |
|
| David Fuhrman | |||
| Chief Executive Officer | |||
3